#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nasopharyngeal cancer Waldenstrom's macroglobulinaemia Eosinophilic oesophagitis Cataract Oesophageal squamous cell carcinoma stage II Breast cancer Epstein-Barr virus infection Congenital ectodermal dysplasia MELAS syndrome Lennox-Gastaut syndrome Chemical burn Anaemia Becker's muscular dystrophy Leber's congenital amaurosis Immune-mediated myasthenia gravis More trials…

    Learn about Rare Diseases

    Haemophilia – Treatment Glycogen storage disease type V – Diagnostics Glomerulonephritis membranoproliferative – Treatment Antithrombin III deficiency – Trials in Disease Alagille syndrome Tuberous sclerosis complex – Life with Disease Richter’s syndrome – Diagnostics Mastocytosis Soft tissue sarcoma Usher’s syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Abbv-668 PIROXICAM Fluoxetine Av-Ec2023 Ab-729 Povidone, Iodinated Tigulixostat Bio89-100 Depemokimab Caplacizumab Teprotumumab Linezolid Tiaprofenic Acid MB-HUCART19.1 Zinc Acexamate Ds-3939A Anselamimab Sargramostim Meropenem Hydroxypropylbetadex More therapies…

    Learn about Your Condition

    Pharyngeal cancer stage III Phaeochromocytoma Viral myocarditis Hepatobiliary cancer Corneal dystrophy Endometrial adenocarcinoma Tooth loss Lip and/or oral cavity cancer Anaemia Multifocal motor neuropathy Pyrexia Chorioretinitis Rhabdoid tumour Breast conserving surgery Mitochondrial myopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Henri Mondor – 1 rue Gustave Eiffel

Hopital Henri Mondor – 1 rue Gustave Eiffel

51 avenue du Mal de Lattre de Tassigny, Creteil, 94010, France

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Acquired ATTR amyloidosis
    Investigated Drugs:
    • Acoramidis Hydrochloride
    Belgium Denmark France Germany Greece Ireland +5

  • Study of Nivolumab and Ipilimumab or Drug Combination for Patients with Metastatic Kidney Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Renal cancer
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    France

  • Study on the Safety and Effectiveness of Nivolumab and Ipilimumab for Patients with Metastatic Colorectal Cancer with dMMR or MSI

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    • Colorectal cancer
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    France

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    Investigated Drugs:
    • D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala
    • Levoleucovorin
    • Mps-102
    France

  • Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Obefazimod
    Belgium France Germany Italy Poland Spain

  • Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Obefazimod
    Belgium France Germany Italy Poland Spain

  • Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Nivolumab
    • Sunitinib
    Bulgaria Croatia Czechia Denmark Finland France +8

  • Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Rilvegostomig
    France

  • Study on the Effects of Tebapivat and AG-946 in Patients with Sickle Cell Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Sickle cell disease
    Investigated Drugs:
    • Ag-946 Phosphate
    Belgium France Ireland The Netherlands

  • Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Risankizumab
    • Vedolizumab
    Austria Bulgaria Croatia Czechia Estonia Finland +14
Previous Page
1 … 4 5 6 7 8 … 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!